Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 5Sarcoma 4Genitourinary 3Dermatologic 3CNS 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Breast 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Gastrointestinal 1

Conditions

Melanoma 3

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × FANG vaccine × Dermatologic × Clear all
NCT00003715 2015-12-03

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

AVAX Technologies

Phase 2 Terminated
425 enrolled
Dermatologic

Melanoma

NCT00436930 2014-01-10

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
200 enrolled
Dermatologic

Melanoma

NCT00004022 2013-04-05

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡